Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?

Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.

    Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y

    Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.

      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

        Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost

        Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.

          Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?

          ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            What's in the Cards for Geron (GERN) This Earnings Season?

            With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

              AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan

              AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.

                Swarup Gupta headshot

                Dow 30 Stock Roundup: Cisco Beats, Caterpillar January Sales up 34%

                The Dow rebounded strongly over the first five trading days after entering correction territory last week.

                  J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

                  J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                    J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

                    J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                      FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

                      The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

                        Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

                        Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.

                          Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

                          Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

                            Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis

                            Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

                              Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18

                              Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.

                                Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

                                Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

                                  Alkermes Submits NDA for Depression Candidate to the FDA

                                  Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).

                                    Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label

                                    Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.

                                      Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

                                      Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.

                                        Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat

                                        Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.

                                          The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

                                          The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

                                            Mark Vickery headshot

                                            Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon

                                            Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).

                                              AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

                                              AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                                Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

                                                J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

                                                  Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric

                                                  Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric